Biosimilar Regulatory Strategy - Biological Vaccine Clinical Trials

Conducting biologics, biosimilar, and vaccine clinical trials in India requires careful alignment with regulatory requirements throughout the development lifecycle. Sponsors must generate robust preclinical data, obtain regulatory approvals through the Central Drugs Standard Control Organization (CDSCO), and conduct phased clinical trials to demonstrate safety, immunogenicity, and efficacy. While challenges such as variability in immune responses, manufacturing complexity, and distribution logistics remain, strategic regulatory planning and strong safety monitoring systems can help ensure the successful development and timely availability of vaccines and biological therapies for public health.

A Guide to Biosimilar Regulatory Strategy & Vaccine Clinical Trials in India

Biological products and vaccines play a critical role in preventing and treating infectious and chronic diseases. However, due to their complex manufacturing processes, immunogenicity concerns, and safety considerations, their clinical development requires a carefully designed regulatory strategy. In India, clinical trials for biologics and vaccines are governed by a structured regulatory framework that ensures safety, efficacy, and quality before market approval.

This article helps sponsors understand regulatory requirements early in biological clinical trials in India, enabling them to design efficient clinical programs, avoid delays, and ensure compliance with national guidelines.

Regulatory Framework Governing Biologicals and Vaccine Clinical Studies in India

The regulatory oversight for drugs, biologics, and vaccines in India is primarily handled by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940, and its associated rules.

Clinical trials are regulated through the New Drugs and Clinical Trials Rules (NDCTR), 2019, which provide a unified framework for new drug approvals, trial permissions, and post-approval monitoring in India.3 Therefore, under the NDCT Rules, biologicals and vaccines must undergo a structured clinical development process before receiving regulatory approval in India.

The final authority responsible for approving clinical trials is the Drugs Controller General of India (DCGI).

These regulations apply to several categories of biological products, including

Vaccines
Recombinant biologics
Monoclonal antibodies
Gene and cell therapies

Key Stages in Regulatory Strategy for Biological & Vaccine Trials

Developing a regulatory strategy for biologicals and vaccine clinical trials approval in India requires planning across the full development lifecycle and includes the following stages:

Preclinical Development

Before human testing begins, sponsors must generate robust preclinical data. Key requirements include:

Toxicology studies
Immunogenicity evaluation
Pharmacodynamic and pharmacokinetic assessments
Proof-of-concept animal studies

These studies demonstrate the safety profile and justify initiating human trials.

Vaccine or Biological Clinical Trial Application Submission

Sponsors must submit a clinical trial application to obtain regulatory approval from CDSCO before conducting human clinical trials.
For this, they need to submit a clinical trial application (Form CT-04) to CDSCO’s Biological Division
through the SUGAM portal. The application typically includes:

Clinical trial protocol
Investigator’s brochure
Chemistry, manufacturing, and controls (CMC) data
Preclinical safety data
Ethics committee approvals
Informed consent documents

After a biological / vaccine clinical trial application submission in India, the application undergoes regulatory review and may be evaluated by the relevant Subject Expert Committee.

Conduct of Biological Clinical Trial Phases

Biologics and vaccines generally follow a stepwise clinical development pathway, where each phase is designed to progressively evaluate safety, immunogenicity, efficacy, and manufacturing readiness before widespread use.

Phase I

Phase I trials are conducted in a small group of healthy volunteers or patients and typically involve initial dose-escalation studies. The expected outcomes from this phase include the generation of data on safety, immunogenicity, dose-escalation, efficacy, manufacturing process, and human study design approvals.

Phase III

Phase III trials are large-scale studies designed to confirm the safety and efficacy of the product. The expected outcomes from the proposed India Phase III include safety and efficacy data, emergency use licensure, lot release, rollout planning, serious adverse event monitoring, cluster randomised control monitoring, and eventual full market authorisation.

Note: For vaccines, clinical endpoints often include disease prevention or validated immunological correlates of protection.

Regulatory Review and Marketing Authorisation

After successful clinical trials, sponsors submit a New Drug Application (NDA) to CDSCO. The submission includes:8

Complete clinical trial data
Safety and immunogenicity data
Manufacturing validation
Quality and stability information

CDSCO reviews the data and may grant marketing approval if the product meets safety, efficacy, and quality requirements.

Post-Marketing Surveillance

Even after approval, vaccines and biologicals require continued monitoring. Post-marketing obligations may include:9

Periodic safety update reports (PSUR)
Risk management plans
Pharmacovigilance reporting
Post-authorisation studies

India has strengthened vaccine pharmacovigilance requirements to monitor adverse events following immunisation and ensure long-term safety.

Challenges in Conducting Vaccine Trials in India

Despite significant progress in vaccine research and immunisation programs, vaccine development and deployment remain complex. Biological variability, regulatory considerations, manufacturing constraints, and infrastructure limitations all influence vaccine clinical development and rollout in India. The key challenges are summarised in Table 1.1

Challenge	Key Issues
Biological variability	Vaccine responses vary across individuals due to age, gender, genetics, lifestyle, and immune status. Infants and older adults (>60 years) often show weaker or different immune responses, and underlying conditions such as diabetes or cancer may also influence vaccine effectiveness.
Variability in immune responses	Immune responses can differ widely among populations, especially in elderly individuals with comorbidities. Some vaccines may also show differences in effectiveness based on genetic variations or immune memory.
Manufacturing limitations	Vaccine production involves complex processes and strict quality control, resulting in a limited number of manufacturers capable of producing vaccines at scale.
Cost and affordability	Vaccine development and manufacturing are expensive, which historically limited access in developing countries, although affordability has improved in recent years.
Vaccine hesitancy and public acceptance	Public scepticism toward vaccines remains a global concern. Vaccine acceptance influences the success of mass immunisation campaigns and the ability to achieve herd immunity.
Global supply and distribution	Ensuring sufficient vaccine supply worldwide is challenging, especially during pandemics. Past outbreaks have shown that wealthier countries may secure a large portion of available vaccine supplies.
Infrastructure challenges in India	Delivering vaccines across India’s large and diverse population can be difficult due to limited laboratory facilities, high costs, inadequate cold chain infrastructure, and transportation challenges.

Short Summary

Biologicals and vaccines require a well-planned regulatory strategy due to their complex manufacturing processes and safety considerations.
In India, clinical trials are regulated by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940, and the New Drugs and Clinical Trials Rules (NDCTR), 2019.
Clinical development follows a stepwise pathway including preclinical studies, clinical trial application submission, and phased clinical trials (Phase I to III).
Each clinical phase generates critical evidence on safety, immunogenicity, efficacy, dose optimisation, and manufacturing readiness.
After successful trials, sponsors submit a New Drug Application (NDA) for regulatory review and marketing authorisation.
Vaccine development and deployment in India face challenges related to biological variability, manufacturing capacity, cost, vaccine hesitancy, and infrastructure limitations.

Conclusion

Developing biologicals and vaccines requires a well-structured regulatory strategy that aligns scientific development with regulatory expectations. In India, clinical trials for biologics and vaccines are governed by a defined framework involving regulatory oversight, ethical review, and structured clinical development phases to ensure safety, efficacy, and quality before market authorisation.

Each stage of clinical development in India, from early safety and immunogenicity assessment to large-scale efficacy trials and eventual licensure, plays a critical role in generating the evidence required for regulatory approval and public health deployment. However, vaccine development is influenced by several challenges, including variability in immune responses, manufacturing complexity, cost considerations, vaccine hesitancy, and logistical barriers in large and diverse populations.

Despite these challenges, India continues to strengthen its regulatory environment and clinical research infrastructure. Sponsors can successfully navigate the development pathway and support the timely availability of safe and effective biologicals and vaccines for public health needs with strategic planning, early regulatory engagement, and strong safety monitoring systems.

References

Salalli R, Dange JR, Dhiman S, Sharma T. Vaccines development in India: advances, regulation, and challenges. Clin Exp Vaccine Res. 2023;12(3):193-208. doi:10.7774/cevr.2023.12.3.193
2016DrugsandCosmeticsAct1940Rules1945.pdf. Accessed March 12, 2026. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf
NEW DRUGS AND CTRS RULE, 2019.pdf. Accessed March 12, 2026. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/new_DC_rules/NEW%20DRUGS%20ANDctrS%20RULE,%202019.pdf
Clinical Research Regulation For India | ClinRegs. Accessed March 12, 2026. https://clinregs.niaid.nih.gov/country/india#
Shen J, Swift B, Mamelok R, Pine S, Sinclair J, Attar M. Design and Conduct Considerations for First‐in‐Human Trials. Clin Transl Sci. 2019;12(1):6-19. doi:10.1111/cts.12582
CDSCO – Revised Guidance for Industry – Stakeholders Comments Website.pdf. Accessed March 12, 2026. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/CDSCO%20-%20Revised%20Guidance%20for%20Industry%20-%20Stakeholders%20Comments%20Website.pdf
Dinda AK, Tripathi SK, John B. Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy. Indian J Med Res. 2020;152(1-2):156-163. doi:10.4103/ijmr.IJMR_3640_20
Update_Checklist_10July2018.pdf. Accessed March 13, 2026. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/New-Drugs/Checklist/Update_Checklist_10July2018.pdf
Draft Guidance for pvpi.pdf. Accessed March 13, 2026. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/Draft%20Guidance%20for%20pvpi.pdf